Letrozole Monotherapy vs. Tamoxifen Monotherapy or vs. Letrozole in Sequence with Tamoxifen for Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

BIG 1-98/IBCSG 18-98

Henning Mouridsen for the **BIG 1-98 Collaborative Group** Coordinated by the

International Breast Cancer Study Group International Breast Cancer Study Group I B C S G SABCS 2008



Disclosure

- BIG 1-98 is coordinated by the International Breast Cancer Study Group and financed by Novartis
- Henning Mouridsen has received fees from Novartis for advisory boards and lectures






BIG 1-98 Worldwide Collaborative

Argentina 123 Australia 667 634 Belgium Brazil 17 Canada 20 Chile /22 Czech Rep. 109 1396 Denmark France 1016 113 Germany 334 Hungary Iceland 6 Italy 1285 94 Netherlands

New Zealand 157 51 Peru 277 Poland Portugal 64 240 Russia Slovenia 15 South Africa 187 Spain 70 Sweden 64 Switzerland 611 Turkey 54 United Kingdom 401 Uruguay TOTAL 8028

BIG 1-98 Overall Design



Previous Analyses:

International Breast Cancer Study Group

IBCSG SABCS 2008

Is 5 years Let superior to 5 years Tam as initial therapy?

- Primary Core Analysis (PCA), Median follow-up 26 months
- Monotherapy Arm Analysis, Median follow-up 51 months

Summary of Previous Analyses

The PCA and monotherapy analyses showed that 5 years upfront letrozole is significantly superior to 5 years of upfront tamoxifen in terms of

- Disease-Free Survival
- Time to Distant Recurrence

BIG 1-98 Collaborative Group, N Engl J Med 2005;353:2747-57 Coates et al, J Clin Oncol 2007;25:486-92






BIG 1-98 New Data to Be Presented

- Monotherapy update
 - Protocol-specified, 10-years from start of study
 - Median follow-up 76 months
- Sequential therapy vs. letrozole
 - Protocol-specified final efficacy analysis (DSMC October 2008)
 - Median follow-up 71 months





BIG 1-98 Monotherapy Update Median Follow-up 76 months








BIG 1-98 Monotherapy Update

- 2005 results of Let superiority led to unblinding of Tam-alone arm
- 619 (25.2%) patients selectively crossed over to Let
 - Mostly in years 3-5
 - Median duration Let after crossover 18 mos.
- This complicates comparisons with Tam alone
- The comparison of Tam vs. Let was done by
 - Intent-to-treat (ITT)
 - Censoring at crossover





BIG 1-98 Monotherapy Update Median Follow-up 76 months



Favors Letrozole Favors Tamoxifen



*Let:Tam: breast cancer events, 321:363 second (non breast) malignancy, 101:115 deaths without prior cancer event, 87:87




BIG 1-98 New Data to Be Presented

- Monotherapy update
 - Protocol-specified, 10-years from start of study
 - Median follow-up 76 months
- Sequential therapy vs. letrozole monotherapy
 - Protocol-specified, final efficacy analysis (DSMC October 2008)
 - Median follow-up 71 months





BIG 1-98 Sequential Therapy




*612 patients (39.5%) selectively crossed over to letrozole after the tamoxifen arm was unblinded. The present analysis includes only 3 blinded arms (B, C, D)



BIG 1-98 Sequential Therapy Two Pairwise Comparisons


- 3 blinded arms
- Sequential vs. letrozole monotherapy
- Evaluated from randomization
- Median Follow Up 71 mos.
- 99% confidence intervals to account for multiple comparisons







BIG 1-98 Sequential Treatment Disease-Free Survival




BREASTINTERNATIONALGROU

Sequential Treatment Comparisons Median Follow-up 71 months

Tam \rightarrow Let vs. Let

Let \rightarrow Tam vs. Let




*Time to distant recurrence






Breast Cancer Events Tam→Let vs. Let



Breast Cancer Events Let→Tam vs. Let



Conclusions

For postmenopausal women with endocrine-responsive breast cancer

- Updated results of BIG 1-98 suggest superior overall survival with letrozole compared with tamoxifen
- Adjuvant endocrine therapy should start with letrozole especially for patients at higher risk for early recurrence
- Patients commenced on letrozole can be switched after 2 years to tamoxifen, if required
- Safety is consistent with known safety profiles of each agent (data not shown)
- Improved therapeutic approaches beyond five years are required to control late relapses





Thanks to ...

- The patients participating in the trial
- The principal investigators
- The co-investigators, data managers, nurses, study coordinators
- The cooperative groups
- The IBCSG Data and Safety Monitoring Committee
- The trial monitors/audit teams
- Novartis





BIG 1-98 Investigators Meeting

December 10, 2008 San Antonio, Texas



